ZYDUS LIFESCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 951.2 INR | +1.90% |
|
+0.68% | +38.02% |
| Apr. 24 | Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection | MT |
| Apr. 23 | China Medical System's Anti-Anaemia NDA Accepted in China | MT |
| Sales 2024 * | 193B 2.31B | Sales 2025 * | 210B 2.53B | Capitalization | 939B 11.28B |
|---|---|---|---|---|---|
| Net income 2024 * | 35.88B 431M | Net income 2025 * | 37.48B 450M | EV / Sales 2024 * | 4.8 x |
| Net cash position 2024 * | 14B 168M | Net cash position 2025 * | 35.09B 421M | EV / Sales 2025 * | 4.3 x |
| P/E ratio 2024 * |
25.9
x | P/E ratio 2025 * |
24.9
x | Employees | 23,026 |
| Yield 2024 * |
0.63% | Yield 2025 * |
0.64% | Free-Float | 24.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zydus Lifesciences Limited
More recommendations
More press releases
| 1 day | +1.90% | ||
| 1 week | +1.52% | ||
| Current month | -5.57% | ||
| 1 month | -6.47% | ||
| 3 months | +29.16% | ||
| 6 months | +65.52% | ||
| Current year | +38.02% |
1 week
913.20
968.05
1 month
913.201 031.70
Current year
686.001 031.70
1 year
484.951 031.70
3 years
319.001 031.70
5 years
202.001 031.70
10 years
174.421 031.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 44 | 97-07-31 | |
| Director of Finance/CFO | - | - | |
| Chairman | 71 | 95-05-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 18-12-05 | |
| Chairman | 71 | 95-05-14 | |
| Director/Board Member | 69 | 97-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 6 M€ | +6.07% | - | |
| 0.01% | 117 M€ | +0.68% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 951.2 | +1.90% | 1 455 928 |
| 24-04-24 | 933.5 | -2.70% | 3,433,345 |
| 24-04-23 | 959.4 | -0.03% | 1,094,642 |
| 24-04-22 | 959.7 | +4.07% | 1,739,090 |
| 24-04-19 | 922.2 | -1.58% | 1,482,222 |
Delayed Quote NSE India S.E., April 25, 2024 at 06:14 am EDT
More quotes
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
933.5
INR
Average target price
839.4
INR
Spread / Average Target
-10.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.02% | 11.27B | |
| +20.70% | 42.78B | |
| +18.59% | 22.25B | |
| +14.49% | 14.39B | |
| +12.83% | 13.55B | |
| -9.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 5.01B | |
| -8.24% | 4.51B |
- Stock Market
- Equities
- ZYDUSLIFE Stock
